<DOC>
	<DOCNO>NCT00492167</DOCNO>
	<brief_summary>RATIONALE : Beta-glucan may stimulate immune system stop tumor cell grow . Monoclonal antibody , 3F8 , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Giving beta-glucan together monoclonal antibody 3F8 may kill tumor cell . PURPOSE : This phase I trial study side effect best dose beta-glucan give together monoclonal antibody 3F8 treating patient metastatic neuroblastoma .</brief_summary>
	<brief_title>Beta-Glucan Monoclonal Antibody 3F8 Treating Patients With Metastatic Neuroblastoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine clinical toxicity beta-glucan combination monoclonal antibody 3F8 patient metastatic neuroblastoma . - Evaluate biologic effect regimen patient . OUTLINE : This dose-escalation study beta-glucan . Patients receive oral beta-glucan daily day -4 12 monoclonal antibody 3F8 IV 30-90 minute day 1-5 8-12 . Treatment repeat every 4 week 4 course absence disease progression unacceptable toxicity human antimouse antibody ( HAMA ) titer &lt; 1,000 U/mL . Cohorts 3-6 patient receive escalate dos beta-glucan maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Patients undergo urine , bone marrow , blood sample collection periodically biological study . Samples analyze antibody-dependent cellular cytotoxicity , complement-mediated cytotoxicity , serum HAMA response via immunohistochemistry . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis neuroblastoma 1 follow method : Histopathology Bone marrow involvement AND elevate urinary catecholamine Highrisk disease , define 1 following : Stage 4 disease MYCN amplification ( age ) without MYCN amplification ( &gt; 18 month age ) MYCNamplified stage 3 disease ( unresectable age ) MYCNamplified stage 4S disease Metastatic disease Tumor progression persistent disease ( metastatic primary site ) intensive conventional chemotherapy Must evaluable ( microscopic marrow metastasis , elevate tumor marker , positive MIBG PET scan ) measurable ( CT scan MRI ) disease document completion prior systemic therapy PATIENT CHARACTERISTICS : Platelet count &gt; 25,000/mm^3 ANC &gt; 500/mm^3 Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No history allergy mouse protein , betaglucan , mushroom , yeast No active lifethreatening infection No severe major organ toxicity Concurrent toxicity must â‰¤ grade 2 except follow , may grade 3 : Myelosuppression Hearing loss Alopecia Anorexia Nausea Hyperbilirubinemia TPN Anxiety Hypomagnesemia No prior HAMA titer &gt; 1,000 U/mL ELISA PRIOR CONCURRENT THERAPY : No concurrent supplemental betaglucan food ( e.g. , bran cereal mushroom ) complementary medicine No concurrent systemic anticancer medication ( e.g. , hormonal agent , chemotherapy , investigational agent , immunotherapy ) Concurrent isotretinoin allow second course study treatment complete patient develops human antimouse antibody ( HAMA )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>recurrent neuroblastoma</keyword>
	<keyword>regional neuroblastoma</keyword>
	<keyword>stage 4S neuroblastoma</keyword>
	<keyword>disseminate neuroblastoma</keyword>
</DOC>